On November 10, 2025, the Tandem Mobi insulin pump system achieved a significant milestone by receiving approval from the Food and Drug Administration (FDA) for compatibility with Android smartphones. This pivotal development broadens the accessibility of the Tandem Mobi mobile app, allowing not only Apple smartphone users but also a wider audience of Android users to benefit from its innovative features.
Innovative Features of Tandem Mobi
Manufactured by Tandem Diabetes Care, the Tandem Mobi is a compact automated insulin delivery (AID) system that can be discreetly worn on the body. The system operates by gathering blood sugar data from the user’s continuous glucose monitoring (CGM) system, enabling the pump to adjust insulin doses based on real-time readings.
“We’re excited to bring Tandem Mobi and the best-in-class outcomes of Control-IQ+ to Android users,” expressed John Sheridan, president and chief executive officer of Tandem Diabetes Care. “This latest integration gives Android users access to the life-changing benefits of Control-IQ+ on a system that emphasizes convenience, discretion, and customization.”
The AID system is powered by Control-IQ+ technology, which has demonstrated remarkable results, helping users achieve up to 79 percent time in range during the day and 90 percent time in range overnight. Users can expect healthier blood sugar readings starting from the very first day of using the device, although individual results may vary.
The Tandem Mobi mobile app is designed with user-friendliness in mind, allowing individuals to manage their diabetes directly from their existing smartphones without the need for additional medical devices. The app ensures secure communication with the Tandem Source platform, facilitating real-time interactions between patients and their healthcare providers. This capability empowers patients to make informed management decisions promptly.
“With the Tandem Mobi mobile app, we’re delivering a solution that meets patients where they are, on the devices they use every day, while maintaining the safety, reliability, and innovation they expect from Tandem,” stated Dr. Jordan Pinsker, chief medical officer.
Nationwide access to the Tandem Mobi system is set to commence in early 2026, with a limited release anticipated in December 2025. Once available, the Tandem Mobi Android app will be accessible for download from the Google Play Store on a variety of smartphones, including Google Pixel models six through ten and Samsung Galaxy models S21 through S25.
For those interested in early access, further information can be found at Tandem Diabetes Care.
